NI201200008A - Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st - Google Patents

Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st

Info

Publication number
NI201200008A
NI201200008A NI201200008A NI201200008A NI201200008A NI 201200008 A NI201200008 A NI 201200008A NI 201200008 A NI201200008 A NI 201200008A NI 201200008 A NI201200008 A NI 201200008A NI 201200008 A NI201200008 A NI 201200008A
Authority
NI
Nicaragua
Prior art keywords
treatment
myocardial infarction
otamixaban
aged
old
Prior art date
Application number
NI201200008A
Other languages
English (en)
Inventor
Stechl Jens
Moryusef Angéle
Gaudin Christophe
Ythier-Moury Pascale
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI201200008A publication Critical patent/NI201200008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere al uso de éster metílico del ácido ( 2R, 3R ) - 2 - ( 3 - carbamimidoil - bencil ) - 3 - [ 4 - ( 1 - oxi - piridin - 4 - il) benzoilamino] - butírico o una sal farmacéuticamente aceptable del mismo, para la preparación de un medicamento para su uso en el infarto de miocardio sin elevación del ST, comprendiendo dicho tratamiento administrar una cantidad terapéuticamente eficaz de éster metílico del ácido ( 2R, 3R ) - 2 - ( 3 - carbamimidoil - bencil ) - 3 - [ 4 - ( 1 - oxi - piridin - 4 - il ) benzoilamino] - butírico o una sal farmacéuticamente aceptable del mismo a un paciente humano, de edad avanzada y/o que muestra insuficiencia renal y/o tiene un bajo peso corporal.
NI201200008A 2009-07-29 2012-01-12 Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st NI201200008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290601 2009-07-29
EP10305192 2010-02-26

Publications (1)

Publication Number Publication Date
NI201200008A true NI201200008A (es) 2012-05-29

Family

ID=42542846

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200008A NI201200008A (es) 2009-07-29 2012-01-12 Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st

Country Status (25)

Country Link
US (1) US9492437B2 (es)
EP (1) EP2459193A1 (es)
JP (1) JP2013500298A (es)
KR (1) KR20120038982A (es)
CN (1) CN102470128A (es)
AR (1) AR077427A1 (es)
AU (1) AU2010277725B2 (es)
BR (1) BR112012001900A2 (es)
CA (1) CA2766533A1 (es)
CL (1) CL2012000196A1 (es)
CO (1) CO6491041A2 (es)
CR (1) CR20110674A (es)
DO (1) DOP2012000012A (es)
EC (1) ECSP12011627A (es)
IL (1) IL217612A (es)
MA (1) MA33455B1 (es)
MX (1) MX2012000457A (es)
NI (1) NI201200008A (es)
NZ (1) NZ597957A (es)
PE (1) PE20121401A1 (es)
RU (1) RU2542455C2 (es)
SG (1) SG177772A1 (es)
TW (1) TWI463982B (es)
UY (1) UY32807A (es)
WO (1) WO2011012527A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2597423C2 (ru) * 2011-03-29 2016-09-10 Санофи Бензойнокислая соль отамиксабана
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
AU2012234323A1 (en) 2011-03-29 2013-10-17 Sanofi Otamixaban formulations with improved stability
CA2883625A1 (en) * 2012-08-31 2014-03-06 Sanofi Otamixaban for use in the treatment of non-st elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1273128C (zh) * 1996-01-02 2006-09-06 阿温蒂斯药物公司 取代的n－[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺
RU2225617C1 (ru) * 2002-12-16 2004-03-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st

Also Published As

Publication number Publication date
NZ597957A (en) 2014-05-30
BR112012001900A2 (pt) 2016-03-15
WO2011012527A1 (en) 2011-02-03
KR20120038982A (ko) 2012-04-24
AU2010277725A1 (en) 2012-02-16
IL217612A (en) 2014-08-31
CN102470128A (zh) 2012-05-23
TWI463982B (zh) 2014-12-11
CR20110674A (es) 2012-04-17
AR077427A1 (es) 2011-08-24
AU2010277725B2 (en) 2016-08-18
JP2013500298A (ja) 2013-01-07
PE20121401A1 (es) 2012-10-25
US9492437B2 (en) 2016-11-15
DOP2012000012A (es) 2012-02-15
MX2012000457A (es) 2012-01-27
SG177772A1 (en) 2012-03-29
RU2542455C2 (ru) 2015-02-20
MA33455B1 (fr) 2012-07-03
EP2459193A1 (en) 2012-06-06
TW201119655A (en) 2011-06-16
UY32807A (es) 2011-02-28
CO6491041A2 (es) 2012-07-31
ECSP12011627A (es) 2012-02-29
CL2012000196A1 (es) 2012-10-05
RU2012107483A (ru) 2013-09-10
US20120238605A1 (en) 2012-09-20
CA2766533A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2016053040A5 (es)
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
EA202091303A2 (ru) Композиция ингибитора jak для местного применения
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201270087A1 (ru) Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
NI201200008A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
CL2009000919A1 (es) Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
EA201291274A1 (ru) Применение антагонистов аденозиновых рецепторов aдля лечения легочной гипертензии